Neue Erkenntnisse für einen Impfstoff gegen alle HIV-Suptypen - 500 Beiträge pro Seite
eröffnet am 08.09.09 20:08:44 von
neuester Beitrag 24.11.09 19:05:04 von
neuester Beitrag 24.11.09 19:05:04 von
Beiträge: 17
ID: 1.152.892
ID: 1.152.892
Aufrufe heute: 0
Gesamt: 1.878
Gesamt: 1.878
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 01.04.24, 10:52 | 381 | |
| gestern 21:20 | 361 | |
| heute 01:24 | 279 | |
| heute 00:34 | 187 | |
| 22.06.20, 20:50 | 174 | |
| gestern 23:03 | 156 | |
| gestern 22:23 | 153 | |
| gestern 19:37 | 144 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.737,36 | -0,56 | 198 | |||
| 2. | 2. | 147,05 | -1,92 | 95 | |||
| 3. | 7. | 6,6320 | -1,43 | 70 | |||
| 4. | 5. | 0,1810 | -1,90 | 51 | |||
| 5. | Neu! | 713,65 | -23,14 | 46 | |||
| 6. | 8. | 3,7700 | +0,80 | 45 | |||
| 7. | 17. | 7,2900 | -0,21 | 43 | |||
| 8. | 4. | 2.390,60 | 0,00 | 41 |
Feedback
International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences
haben in Ländern südlich der Sahara mit einem Screening-Test von Monogram (soweit keine Börsennotierung gefunden) und einem erweiterten Immunotest von Thereclone 2 Antikörper finden können, die an allen Subtypen der AIDS-Viren andokten.
Die bisherigen Bemühungen richteten sich einfach gegen die falschen Antigene, also die wie beim Grippe-Virus sich leicht mutieren und damit den Impfstoff untauglich machten.
In einem Nebensatz wurde auch noch erwähnt, dass IAVI ca 4 Mio Dollar zur weiteren Forschung gesponsort bekommt und Genvec den Auftrag erhalten habe, die Forschungen voranzubringen, verbunden mit eier ersten Zahlung.
Nun wird natürlich noch eine lange Zeit vergehen, bevor irgendwelche Resultate vorliegen um einen Impfstoff aus diesen Erkenntnisen zu produzieren.
Vielleicht 2 Jahre und dann kommen die Studien. Im Idealfall würden also noch 7-10 Jahre ins Land gehen. Dennoch, das ist nicht das einzige Projekt der Genvec.
Eine kleine Einstiegsposition habe ich mir gegönnt.
In diesem Fall ein klares superlang-Investment.
haben in Ländern südlich der Sahara mit einem Screening-Test von Monogram (soweit keine Börsennotierung gefunden) und einem erweiterten Immunotest von Thereclone 2 Antikörper finden können, die an allen Subtypen der AIDS-Viren andokten.
Die bisherigen Bemühungen richteten sich einfach gegen die falschen Antigene, also die wie beim Grippe-Virus sich leicht mutieren und damit den Impfstoff untauglich machten.
In einem Nebensatz wurde auch noch erwähnt, dass IAVI ca 4 Mio Dollar zur weiteren Forschung gesponsort bekommt und Genvec den Auftrag erhalten habe, die Forschungen voranzubringen, verbunden mit eier ersten Zahlung.
Nun wird natürlich noch eine lange Zeit vergehen, bevor irgendwelche Resultate vorliegen um einen Impfstoff aus diesen Erkenntnisen zu produzieren.
Vielleicht 2 Jahre und dann kommen die Studien. Im Idealfall würden also noch 7-10 Jahre ins Land gehen. Dennoch, das ist nicht das einzige Projekt der Genvec.
Eine kleine Einstiegsposition habe ich mir gegönnt.
In diesem Fall ein klares superlang-Investment.
Antwort auf Beitrag Nr.: 37.941.340 von dottore am 08.09.09 20:08:44hier noch die Quellen:
GenVec, Inc. (Gaithersburg, MD; 240-632-5533) announced that it has signed a contract with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under which GenVec will use its proprietary adenovector technology for the development and manufacture of clinical grade preventative AIDS vaccine candidates. The contract, which extends a previous Letter Contract, has a life of up to three years and a potential value of $10.2 million.
Science, Published online September 3, 2009.
By examining blood samples donated by infected people in developing countries, US researchers have found two new powerful antibodies to HIV that open the door to a new and effective AIDS vaccine. The antibodies, called PG9 and PG16, are of a type known as bNAbs (broadly neutralizing antibodies) and exploit an "Achilles heel" or vulnerable spot in the HIV that could be an effective target for a vaccine, said the researchers.
The discovery was made by researchers working at and with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences, and was published on 3 September as an online advanced issue in Science.
Co-principal investigator Wayne Koff, who is senior vice president of research and development at IAVI in New York, told the media:
"The findings themselves are an exciting advance toward the goal of an effective AIDS vaccine because now we've got a new, potentially better target on HIV to focus our efforts for vaccine design."
He said now they've found this target they can look for more, and speed up global efforts to develop an effective AIDS vaccine.
The discovery relied on a global collaboration that developed a new way of looking for bNAbs, and the researchers fully expect more to be found, revealing further vulnerable spots on HIV for vaccines to target.
Only a small proportion of people infected with HIV produce bNAbs, a range of antibodies that are different to other antibodies because they effectively neutralize a high proportion of the HIV types in circulation around the world.
Animal experiments suggest that if the body can "learn" to produce these types of antibody, which is what an effective AIDS vaccine induces, then it is able to protect itself from infection by HIV.
Other bNAbs against HIV have been discovered before, but PG9 and PG16 are the first to be isolated in over 10 years from donors in developing countries, where most new HIV infections occur. Also, the previously identified bNAbs bind to spots on the virus that are hard to target with vaccines.
One of the other co-principal investigators, Dennis Burton, who is professor of immunology and microbial science and scientific director of the IAVI Neutralizing Antibody Center at The Scripps Research Institute in La Jolla, California, said:
"These new antibodies, which are more potent than other antibodies described to date while maintaining great breadth, attach to a novel, and potentially more accessible site on HIV to facilitate vaccine design."
"So now we may have a better chance of designing a vaccine that will elicit such broadly neutralizing antibodies, which we think are key to successful vaccine development," added Burton, who is also a member of the newly established Ragon Institute of MGH, MIT and Harvard.
For a vaccine to be effective it must be able to stimulate the immune system to make broad spectrum antibodies that can effectively neutralize as many forms of the virus as possible. Ability to stimulate high potency antibodies also makes it more likely that the vaccine does not need to stimulate production of too many antibodies to make it effective.
One of the features of HIV that gives it an advantage, is a viral "spike" that it uses to invade cells. The "spike" foils attack by the immune system because it relies on two glycoproteins, gp120 and gp41, which keep changing. This is a successful tactic for HIV because by the time the immune system has noticed the new version of the spike and made new antibodies to attack it, the virus has invaded enough host cells to allow it to replicate in large numbers and overwhelm the immune system.
But PG9 and PG16 attack a part of the "viral spike" of the HIV: specifically they attack regions of gp120 that don't change, and this is probably why they are broad spectrum neutralizers.
There are probably two main reasons why the researchers were able to discover PG9 and PG16: one was the high number of blood samples they were able to access from a range of developing countries, and the other was they used a new way of testing whether bNAbs bind to gp120 and gp41.
The blood samples the researchers used were donated by HIV-infected volunteers from IAVI-supported clinical research centers based in seven sub-Saharan countries as well as in Thailand, Australia, the UK and the US.
The conventional way of testing the ability of bNAbs to bind to gp120 and gp41 uses soluble forms of the proteins, and if Koff, Burton and colleagues had used it they would probably have rejected PG9 and PG16 as candidate bNAbs because they bind weakly to soluble forms of the proteins. But they used a new method that relies on a micro-neutralization assay developed jointly by Monogram Biosciences and IAVI which they ran in parallel with the standard binding assays.
This new method is likely to make a significant difference to the way bNAbs are screened in the future, because it allows researchers to screen bNAbs directly for their ability to block HIV infection.
Another important aspect of the work was the contribution of Theraclone Sciences, a company that was initially working outside of the HIV field, but they had a relevant and unique high throughput process that could be adapted to isolate the effective bNAbs in a much shorter time. Funding from IAVI's Innovation Fund, which is co-funded by the Bill & Melinda Gates Foundation helped to pay for the adaptation.
The process that the Theraclone team used exposes all the antibodies in a blood sample from an HIV infected person, identifies those with broadly neutralizing potential and traces them to their corresponding antibody-forming cells. With recombinant DNA technology, they isolated genes from the candidate bNAbs so they could clone them in large numbers for testing.
Chief scientific officer and senior vice president of Theraclone Sciences, Matthew Moyle, said:
"It is exciting that we were able to use our technology to identify and isolate these new bNAbs, which may offer important clues that could help create an effective AIDS vaccine."
"Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target."
Laura M. Walker, Sanjay K. Phogat, Po-Ying Chan-Hui, Denise Wagner, Pham Phung, Julie L. Goss, Terri Wrin, Melissa D. Simek, Steven Fling, Jennifer L. Mitcham, Jennifer K. Lehrman, Frances H. Priddy, Ole A. Olsen, Steven M. Frey, Phillip W. Hammond, Protocol G Principal Investigators, Stephen Kaminsky, Timothy Zamb, Matthew Moyle, Wayne C. Koff, Pascal Poignard, and Dennis R. Burton.
GenVec, Inc. (Gaithersburg, MD; 240-632-5533) announced that it has signed a contract with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under which GenVec will use its proprietary adenovector technology for the development and manufacture of clinical grade preventative AIDS vaccine candidates. The contract, which extends a previous Letter Contract, has a life of up to three years and a potential value of $10.2 million.
Science, Published online September 3, 2009.
By examining blood samples donated by infected people in developing countries, US researchers have found two new powerful antibodies to HIV that open the door to a new and effective AIDS vaccine. The antibodies, called PG9 and PG16, are of a type known as bNAbs (broadly neutralizing antibodies) and exploit an "Achilles heel" or vulnerable spot in the HIV that could be an effective target for a vaccine, said the researchers.
The discovery was made by researchers working at and with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences, and was published on 3 September as an online advanced issue in Science.
Co-principal investigator Wayne Koff, who is senior vice president of research and development at IAVI in New York, told the media:
"The findings themselves are an exciting advance toward the goal of an effective AIDS vaccine because now we've got a new, potentially better target on HIV to focus our efforts for vaccine design."
He said now they've found this target they can look for more, and speed up global efforts to develop an effective AIDS vaccine.
The discovery relied on a global collaboration that developed a new way of looking for bNAbs, and the researchers fully expect more to be found, revealing further vulnerable spots on HIV for vaccines to target.
Only a small proportion of people infected with HIV produce bNAbs, a range of antibodies that are different to other antibodies because they effectively neutralize a high proportion of the HIV types in circulation around the world.
Animal experiments suggest that if the body can "learn" to produce these types of antibody, which is what an effective AIDS vaccine induces, then it is able to protect itself from infection by HIV.
Other bNAbs against HIV have been discovered before, but PG9 and PG16 are the first to be isolated in over 10 years from donors in developing countries, where most new HIV infections occur. Also, the previously identified bNAbs bind to spots on the virus that are hard to target with vaccines.
One of the other co-principal investigators, Dennis Burton, who is professor of immunology and microbial science and scientific director of the IAVI Neutralizing Antibody Center at The Scripps Research Institute in La Jolla, California, said:
"These new antibodies, which are more potent than other antibodies described to date while maintaining great breadth, attach to a novel, and potentially more accessible site on HIV to facilitate vaccine design."
"So now we may have a better chance of designing a vaccine that will elicit such broadly neutralizing antibodies, which we think are key to successful vaccine development," added Burton, who is also a member of the newly established Ragon Institute of MGH, MIT and Harvard.
For a vaccine to be effective it must be able to stimulate the immune system to make broad spectrum antibodies that can effectively neutralize as many forms of the virus as possible. Ability to stimulate high potency antibodies also makes it more likely that the vaccine does not need to stimulate production of too many antibodies to make it effective.
One of the features of HIV that gives it an advantage, is a viral "spike" that it uses to invade cells. The "spike" foils attack by the immune system because it relies on two glycoproteins, gp120 and gp41, which keep changing. This is a successful tactic for HIV because by the time the immune system has noticed the new version of the spike and made new antibodies to attack it, the virus has invaded enough host cells to allow it to replicate in large numbers and overwhelm the immune system.
But PG9 and PG16 attack a part of the "viral spike" of the HIV: specifically they attack regions of gp120 that don't change, and this is probably why they are broad spectrum neutralizers.
There are probably two main reasons why the researchers were able to discover PG9 and PG16: one was the high number of blood samples they were able to access from a range of developing countries, and the other was they used a new way of testing whether bNAbs bind to gp120 and gp41.
The blood samples the researchers used were donated by HIV-infected volunteers from IAVI-supported clinical research centers based in seven sub-Saharan countries as well as in Thailand, Australia, the UK and the US.
The conventional way of testing the ability of bNAbs to bind to gp120 and gp41 uses soluble forms of the proteins, and if Koff, Burton and colleagues had used it they would probably have rejected PG9 and PG16 as candidate bNAbs because they bind weakly to soluble forms of the proteins. But they used a new method that relies on a micro-neutralization assay developed jointly by Monogram Biosciences and IAVI which they ran in parallel with the standard binding assays.
This new method is likely to make a significant difference to the way bNAbs are screened in the future, because it allows researchers to screen bNAbs directly for their ability to block HIV infection.
Another important aspect of the work was the contribution of Theraclone Sciences, a company that was initially working outside of the HIV field, but they had a relevant and unique high throughput process that could be adapted to isolate the effective bNAbs in a much shorter time. Funding from IAVI's Innovation Fund, which is co-funded by the Bill & Melinda Gates Foundation helped to pay for the adaptation.
The process that the Theraclone team used exposes all the antibodies in a blood sample from an HIV infected person, identifies those with broadly neutralizing potential and traces them to their corresponding antibody-forming cells. With recombinant DNA technology, they isolated genes from the candidate bNAbs so they could clone them in large numbers for testing.
Chief scientific officer and senior vice president of Theraclone Sciences, Matthew Moyle, said:
"It is exciting that we were able to use our technology to identify and isolate these new bNAbs, which may offer important clues that could help create an effective AIDS vaccine."
"Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target."
Laura M. Walker, Sanjay K. Phogat, Po-Ying Chan-Hui, Denise Wagner, Pham Phung, Julie L. Goss, Terri Wrin, Melissa D. Simek, Steven Fling, Jennifer L. Mitcham, Jennifer K. Lehrman, Frances H. Priddy, Ole A. Olsen, Steven M. Frey, Phillip W. Hammond, Protocol G Principal Investigators, Stephen Kaminsky, Timothy Zamb, Matthew Moyle, Wayne C. Koff, Pascal Poignard, and Dennis R. Burton.
Antwort auf Beitrag Nr.: 37.941.340 von dottore am 08.09.09 20:08:44Seit Jahrzehnten wird nach einem Heilmittel gegen Krebs gesucht
und trotzdem sterben mehr Menschen an Krebs als je zuvor.
AIDS ist wohl ebenfalls sehr schwierig anzugehen.
Da irgendwelche Hoffnungen zu hegen, scheint töricht zu sein.
Diese beiden Krankheiten sind ein Ausdruck dieser Zeit.
und trotzdem sterben mehr Menschen an Krebs als je zuvor.
AIDS ist wohl ebenfalls sehr schwierig anzugehen.
Da irgendwelche Hoffnungen zu hegen, scheint töricht zu sein.
Diese beiden Krankheiten sind ein Ausdruck dieser Zeit.
Antwort auf Beitrag Nr.: 37.942.352 von Goldwalla am 08.09.09 22:27:21Kennst Du Dr. Hamer?
Antwort auf Beitrag Nr.: 37.942.352 von Goldwalla am 08.09.09 22:27:21dein Beitrag ist hier fehl am Platz!
Auf einem Forum für Philosophie oder Religion oder Esotherik wärst du besser aufgehoben. Eine Hoffnung zu haben ist doch nicht so töricht, wie dies als töricht zu bezeichnen.
Auf einem Forum für Philosophie oder Religion oder Esotherik wärst du besser aufgehoben. Eine Hoffnung zu haben ist doch nicht so töricht, wie dies als töricht zu bezeichnen.
Trading Spotlight
Antwort auf Beitrag Nr.: 37.942.557 von MrRipley am 08.09.09 23:08:15Ich habe von ihm und über ihn gelesen.
Der ganzheitliche Ansatz ist aber nicht alles,
eine gute Medizinierung ist genauso wichtig.
Aber bei Krebs ist es sehr schwierig, oder fast unmöglich,
da die Patienten eigentlich das ganze bisherige Verhalten umstülpen müßten, auch die Ernährung, und das ist oft bei älteren Patienten zu viel verlangt.
Deswegen habe ich bei allen Krebsheilmittel so meine Zweifel.
Der ganzheitliche Ansatz ist aber nicht alles,
eine gute Medizinierung ist genauso wichtig.
Aber bei Krebs ist es sehr schwierig, oder fast unmöglich,
da die Patienten eigentlich das ganze bisherige Verhalten umstülpen müßten, auch die Ernährung, und das ist oft bei älteren Patienten zu viel verlangt.
Deswegen habe ich bei allen Krebsheilmittel so meine Zweifel.
Antwort auf Beitrag Nr.: 37.943.780 von dottore am 09.09.09 09:50:39Teilweise hast Du natürlich recht,
aber kannst Du eine chronische Erkrankung von seelischen Ursachen
trennen?
Was ist eine Hoffnung?
Ist sie nicht eine Bewegung in die Zukunft?
Braucht sie nicht ein Ziel, daher ein Weg, daher Zeit?
Wäre daher die akzeptierte Hoffnungslosigkeit nicht wesentlich besser,
da in dem sich einstellenden Zustand des Hier und Jetzt eine größere
Kraft und Einsicht über seine eigene Situation sich entfalten könnte?
aber kannst Du eine chronische Erkrankung von seelischen Ursachen
trennen?
Was ist eine Hoffnung?
Ist sie nicht eine Bewegung in die Zukunft?
Braucht sie nicht ein Ziel, daher ein Weg, daher Zeit?
Wäre daher die akzeptierte Hoffnungslosigkeit nicht wesentlich besser,
da in dem sich einstellenden Zustand des Hier und Jetzt eine größere
Kraft und Einsicht über seine eigene Situation sich entfalten könnte?
also das Interesse ist in USA schon da, aber der Kurs steigt eher bescheiden, immerhin so wie ich es mir wünsche.
gestern über 1 Mio Stücke gehandelt und heute werden es wohl 2 Mio werden. Den Kurs sehe ich dann auch bald bei 1 Dollar
gestern über 1 Mio Stücke gehandelt und heute werden es wohl 2 Mio werden. Den Kurs sehe ich dann auch bald bei 1 Dollar
Antwort auf Beitrag Nr.: 37.947.184 von dottore am 09.09.09 16:05:09upps schon weit über 2 Mio Stücke
anhaltend hohes Interesse an dieser Aktie seit meiner Vorstellung hier. Natürlich nicht wegen meiner Vorstellung, sondern wegen der Informationen. Da die ein wenig versteckt waren zu Anfang, kommt das Interesse gering verzögert. Schöne Entwicklung für ein Langzeit-Invest.
der Kurs ist wieder zurück gekommen. Eigentlich eine Einstiegschance, aber da ich es als ultralonginvest sehe, warte ich noch ein paar Monate um nicht mein Kapital zu fesseln.
Hoffentlich bereue ich das nicht, schließlich hat Genvec auch noch anderes in der Pipe
Hoffentlich bereue ich das nicht, schließlich hat Genvec auch noch anderes in der Pipe
GAITHERSBURG, Md., Sept. 30 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the research of a new approach to treating metastatic cancer. Under this grant, valued at over $300,000, GenVec will investigate the hypothesis that the delivery of a specific gene will stimulate an antitumor response that could control cancer metastases.
"Funding from this grant provides GenVec with an opportunity to expand our cancer program and explore a novel approach to cancer treatment," said Dr. Douglas Brough, GenVec's Executive Director, Head of Research. "The work expected to be conducted under this grant will explore new ways to control metastases, addressing a severely unmet medical need."
"Funding from this grant provides GenVec with an opportunity to expand our cancer program and explore a novel approach to cancer treatment," said Dr. Douglas Brough, GenVec's Executive Director, Head of Research. "The work expected to be conducted under this grant will explore new ways to control metastases, addressing a severely unmet medical need."
huihh, heut gehts mal wieder up...
Da ist wohl was in der Pipline.
Da ist wohl was in der Pipline.
nach dem heutigen fulminanten Anstieg ging es doch noch ins Minus.
Damit habe ich wirklich nicht gerechnet.
Ist insofern unwichtig, als as ich nur eine erste Position zu 0,76 habe und in den kommenden Monaten und Jahren bei Schwäche nachlegen will - wenn ich gerade etwas übrig habe
Damit habe ich wirklich nicht gerechnet.
Ist insofern unwichtig, als as ich nur eine erste Position zu 0,76 habe und in den kommenden Monaten und Jahren bei Schwäche nachlegen will - wenn ich gerade etwas übrig habe
im derzeitigen Börsenimfeld auch mal schön, wenn man auf einen Edelstein aufmerksam gemacht wird
GenVec to Present at the BIO Investor Forum
Download image GAITHERSBURG, Md., Oct. 22 /PRNewswire-FirstCall/ -- Today GenVec, Inc. (Nasdaq: GNVC) announced that Paul H. Fischer, Ph.D., President and CEO, will present a company overview highlighting recent developments at the BIO Investor Forum on Thursday, October 29, 2009 at 12:00 pm PST at The Palace Hotel in San Francisco, CA.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )
A webcast of Dr. Fischer's presentation will be available both live and on replay. To access either the live or archived webcast, log on to GenVec's website at www.genvec.com, click on "Investor Relations," and proceed to "Webcasts & Data." The replay will be available 24 hours after the live presentation and will be accessible for 30 days.
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
Investor Contact: Media Contact:
GenVec, Inc. Tiberend Strategic Advisors, Inc.
Danielle M. DiPirro Andrew Mielach
(301) 944-1877 (212) 827-0020
ddipirro@genvec.com amielach@tiberendstrategicadvisors.com
SOURCE GenVec, Inc.
GenVec to Present at the BIO Investor Forum
Download image GAITHERSBURG, Md., Oct. 22 /PRNewswire-FirstCall/ -- Today GenVec, Inc. (Nasdaq: GNVC) announced that Paul H. Fischer, Ph.D., President and CEO, will present a company overview highlighting recent developments at the BIO Investor Forum on Thursday, October 29, 2009 at 12:00 pm PST at The Palace Hotel in San Francisco, CA.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )
A webcast of Dr. Fischer's presentation will be available both live and on replay. To access either the live or archived webcast, log on to GenVec's website at www.genvec.com, click on "Investor Relations," and proceed to "Webcasts & Data." The replay will be available 24 hours after the live presentation and will be accessible for 30 days.
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
Investor Contact: Media Contact:
GenVec, Inc. Tiberend Strategic Advisors, Inc.
Danielle M. DiPirro Andrew Mielach
(301) 944-1877 (212) 827-0020
ddipirro@genvec.com amielach@tiberendstrategicadvisors.com
SOURCE GenVec, Inc.
Antwort auf Beitrag Nr.: 38.233.369 von dottore am 22.10.09 16:51:26Auffälliges Handelsvolumen bei der Aktie mit steigenden Kursen.
Womöglich besteht auch ein Zusammenhang mit der Mutation des neuen H1N1-Virus und fatalen Krankheitsverläufen.
M.
Womöglich besteht auch ein Zusammenhang mit der Mutation des neuen H1N1-Virus und fatalen Krankheitsverläufen.
M.
Antwort auf Beitrag Nr.: 38.447.446 von Macrocosmonaut am 24.11.09 18:57:37Das ist ein kranker Witz, der durch die kranken Medien geistert. 
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 191 | ||
| 93 | ||
| 66 | ||
| 50 | ||
| 46 | ||
| 42 | ||
| 40 | ||
| 37 | ||
| 35 | ||
| 27 |
| Wertpapier | Beiträge | |
|---|---|---|
| 23 | ||
| 21 | ||
| 20 | ||
| 20 | ||
| 19 | ||
| 19 | ||
| 18 | ||
| 18 | ||
| 16 | ||
| 15 |
